Home
About Us
Issues
Authors
Reviewers
Users
Subscription
Our Other Journals
Site map
Aims and Scope
Salient Features
Editorial Board
Editorial Statements
Editorial-PeerReview Process
Publication Ethics & Malpractice
Ijars Performance
Journal Policy
Contact Us
Current Issue
Forthcoming
Article Archive
Access Statistics
Simple Search
Advanced Search
Submit an Article
Instructions
Assistance
Publication Fee
Paid Services
Apply As Reviewer
Acknowledgment
Register Here Edit Register
Register For Article Submission
Login Here Logout
Login For Article Submission
Annual
Buy One Issue
Payment Options
How to Order
JCDR
IJNMR
NJLM

 

Welcome : Guest

Users Online :

 

 

 

 

 

 

 

 

Original article / research

2023
Year :2023 Month : July-August Volume : 12 Issue : 4 Page : SR01 - SR07

Barcelona Clinic Liver Cancer: A Narrative Review

Published: July 1, 2023 | DOI: https://doi.org/10.7860/JCDR/2023/61875.2899
Correspondence Address :
Nitin Kumar Patel, R Desai, Aseem Majumdar,
Dr. R Desai,
Associate Professor, Department of Surgery, Ayaan Institute of Medical Sciences, Moinabad, Telangana, India.
E-mail: desai@live.in
Introduction: To plan therapies for Hepatocellular Carcinoma (HCC), staging methods are necessary. The most often employed HCC management recommendation is the Barcelona Clinic Liver Cancer (BCLC) staging system. Transarterial Chemoembolisation (TACE) is the go-to therapy for BCLC stage B (intermediate HCC). Numerous studies back the use of TACE in individuals with early and advanced HCC. TACE may be an option for individuals who are not candidates for Radiofrequency Ablation (RFA) or Hepatic Resection (HR) for BCLC stage 0 (very early HCC). TACE with RFA offers superior local tumour suppression than RFA alone in BCLC stage. Patients awaiting liver transplants may benefit from TACE as a bridging treatment. When compared to supportive care approaches, TACE improves survival for BCLC-B patients. Patients with BCLC-C stage HCC are treated in the first instance with sorafenib. The combination of sorafenib and TACE has demonstrated efficacy in slowing the development of tumours. Patients with HCC and portal venous thrombosis have superior survival results with TACE combined with radiation. Taking all of these facts into account, it is obvious that TACE, either alone or in conjunction with other therapies, plays a crucial part in the treatment of HCC at every stage. Patients with HCC should get a variety of treatments, and the best TACE candidates should be chosen using a more accurate patient classification approach.
 
[ FULL TEXT ]   |   [ ]
 

Article Utilities

  • Readers Comments
  • Article in PDF
  • Citation Manager
  • Article Statistics
  • Link to PUBMED
  • Print this Article
  • Send to a Friend

Quick Links

REVIEWER
ACCESS STATISTICS
Home  |  About Us  |  Online First  |  Current Issue  |  Simple Search  |  Advance Search  |  Register  |  Login  |  Contact  |  Privacy Policy  |  Terms of Use
Author Support  |  Submit Manuscript  |  IJARS Pre-Publishing  |  Reviewer  |  Articles Archive  |  Access Statistics
©INTERNATIONAL JOURNAL OF ANATOMY RADIOLOGY & SURGERY (IJARS), ISSN : 2277-8543.
EDITORIAL OFFICE : 1/9, Roop Nagar, Delhi 11000. Phone : 01123848553

* This Journal is owned and run by medical professionals *